These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Differences in medical expenditure according to drug prices. Ueshima H Hypertens Res; 2006 May; 29(5):301-2. PubMed ID: 16832148 [No Abstract] [Full Text] [Related]
6. Discrepancies between use of antihypertensive drugs and guidelines indications: pharmacoeconomic implications. Robbiano L; Martelli A; Brambilla G J Hum Hypertens; 2005 Oct; 19(10):819-22. PubMed ID: 15951739 [No Abstract] [Full Text] [Related]
7. [A reply on subsidizing of antihypertensive agents: the problem is exceptional undertreatment of hypertension]. Willenheimer R; Nyström F; Berggren B; Lindström T; Cizinsky S; Weiss L Lakartidningen; 2008 Oct 22-28; 105(43):3055-6. PubMed ID: 19024623 [No Abstract] [Full Text] [Related]
8. NIH promotes use of lower cost drugs for hypertension. Spurgeon D BMJ; 2004 Mar; 328(7439):539. PubMed ID: 15001483 [No Abstract] [Full Text] [Related]
9. [No value for money with certain antihypertensive agents]. Edling A; Löfmark R; Vinge E; Carlsson P; André M; Melltorp G; Edhag O; Dahlqvist R; Andersson I; Magnusson D Lakartidningen; 2008 Nov 26-Dec 9; 105(48-49):3565. PubMed ID: 19133587 [No Abstract] [Full Text] [Related]
10. Unease on industry's role in hypertension debate. Saul S N Y Times Web; 2006 May; ():A1, C9. PubMed ID: 16752458 [No Abstract] [Full Text] [Related]
11. [Innovation or pseudo-innovation: that is the question]. Unger T Med Klin (Munich); 2006 Mar; 101(3):257-62. PubMed ID: 16648986 [No Abstract] [Full Text] [Related]
12. Out-of-pocket costs to users: medicine options for hypertension. Arredondo A Am J Hypertens; 2008 May; 21(5):492. PubMed ID: 18437138 [No Abstract] [Full Text] [Related]
13. Drugs for hypertension. Med Lett Drugs Ther; 1999 Mar; 41(1048):23-8. PubMed ID: 10092931 [No Abstract] [Full Text] [Related]
14. [Drug committees welcome the SBU hypertension report. A number of patients can be offered cost-effective, evidence-based therapy]. Ohlsson O Lakartidningen; 2004 Dec; 101(49):3984-5. PubMed ID: 15633336 [No Abstract] [Full Text] [Related]
15. [Pharmacotherapy of hypertension. How much can safely be saved?]. Anlauf M MMW Fortschr Med; 2004 Apr; 146(15):57-8. PubMed ID: 15373022 [No Abstract] [Full Text] [Related]
16. [Research and marketing]. Meland E; Hernborg A Tidsskr Nor Laegeforen; 2004 Jul; 124(13-14):1820. PubMed ID: 15229677 [No Abstract] [Full Text] [Related]
17. [Tax payers have payed billions for the "blood pressure maffia's" actions]. Järhult B; Lindahl SO Lakartidningen; 2003 May; 100(21):1917-8. PubMed ID: 12815880 [No Abstract] [Full Text] [Related]
18. [Real and assumed potential savings in antihypertensive treatment. Right out of the magician's hat]. Anlauf M; Hense HW Dtsch Med Wochenschr; 2003 Jul; 128(28-29):1557-9. PubMed ID: 12854069 [No Abstract] [Full Text] [Related]
19. [Comment on IOWiG report plan. A medical decision may not be replaced]. Vorstand der Deutschen Hochdruckliga E.V MMW Fortschr Med; 2006 May; 148(19):42. PubMed ID: 16736705 [No Abstract] [Full Text] [Related]
20. Angiotensin receptor blockers: impact on costs of care. Am J Manag Care; 2005 Nov; 11(13 Suppl):S400-3. PubMed ID: 16300456 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]